In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption
在胰腺癌中，西妥昔单抗/曲妥珠单抗双重靶向EGFR/HER2的治疗效果优于曲妥珠单抗/厄洛替尼或拉帕替尼单药治疗：这可能与受体下调和二聚体破坏有关。
期刊:Neoplasia
影响因子:7.7
doi:10.1593/neo.111602
Larbouret, Christel; Gaborit, Nadège; Chardès, Thierry; Coelho, Mickaël; Campigna, Emmanuelle; Bascoul-Mollevi, Caroline; Mach, Jean-Pierre; Azria, David; Robert, Bruno; Pèlegrin, André
